Kornimate/medical-research-clean huggingface dataset:
adipose-derived stem cells (adscs) for moderate to severe chronic kidney disease

Conditions: Moderate to Severe Chronic Kidney Disease

Summary: 1. to assess the safety of allogeneic injection of expanded adscs to patients with moderate to severe chronic kidney disease 2. to assess the efficacy of allogeneic injection of expanded adscs to patients with moderate to severe chronic kidney disease


Eligibility criteria:
inclusion criteria: a patient is eligible for the study if all of the followings apply: 1. aged 20-80 years (inclusive) 2. with chronic kidney disease (ckd)stage 3b to 4 (egfr 15 to 44 ml/min/1.73m2 (inclusive)) note : egfr = estimated glomerular filtration rate 3. having provided informed consent exclusion criteria: any patient meeting any of the exclusion criteria will be excluded from study participation. 1. ascertained hypersensitivity to any component used in the study note: including gentamicin, dmso, agglutex (heperin) 2. with inadequate hematologic function with: absolute neutrophil count (anc) \<1,500/μl or platelets \< 100,000/μl or hemoglobin \< 8 g/dl 3. with inadequate hepatic function with: serum bilirubin, aspartate aminotransferase (ast), alanine aminotransferase (alt) or alkaline phosphatase (akp) \> 2.5 x the institutional upper limit of normal (uln) 4. with hemoglobin a1c (hba1c) \> 8.0% 5. with serious prior or ongoing medical conditions (e.g. concomitant illness such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ecg findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the patient 6. pregnant or lactating women or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period 7. with body mass index (bmi) greater or equal to 36 kg/m2 8. with known history of human immunodeficiency virus (hiv) infection or any type of hepatitis 9. judged to be not applicable to this study by investigator such as difficulty of follow-up observation 10. with any other serious diseases/medical history considered by the investigator not in the condition to enter the trial 11. having participated other investigational study within 4 weeks of entering this study 12. known or suspected abuse of alcohol or narcotics 13. with known history of cancer within past 5 years 14. with any autoimmune disease 15. with cystic kidney disease or requiring kidney dialysis 16. with precancerous condition or with cancer within past 5 years before screening visit
ropinirole controlled release (cr) as an adjunctive agent in the treatment of major depression

Conditions: Depressive Disorder, Major

Summary: this is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. ropinirole cr would be taken in conjunction with current antidepressant medication. patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

we hope to learn whether ropinirole cr (controlled release formulation) is safe and effective when taken with an antidepressant to reduce the symptoms of depression. adults who have a diagnosis of major depression and are currently taking an adequate dose of antidepressant medication will be sought for participation. they will continue to take the antidepressant medication and will receive ropinirole cr, an investigational medication, for eight weeks during which information will be collected about mood and cognitive functioning.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years old * currently experiencing major depression * on at least an adequate dose of fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, bupropion, mirtazapine or duloxetine for at least 6 weeks (monotherapy). exclusion criteria:1. pregnant females or females of child bearing years not using adequate birth control in the opinion of the investigators * known sensitivity to ropinirole * significant medical conditions that would preclude safe participation in the study in the opinion of the investigators. * significant abnormalities observed in screening laboratory evaluation
tens in persons with ms

Conditions: Multiple Sclerosis

Summary: persons with multiple sclerosis (pwms) often have an increased sense of fatigue. furthermore, they present walking difficulties which negatively affects their mobility and results in an additional increase of fatigue. previous literature suggests that transcutaneous electrical nerve stimulation (tens) of leg muscles might increase their walking capacity and decrease perception of fatigue. in the present study we aim to investigate whether tens of leg muscles reduces walking difficulties and sense of fatigue in pwms in comparison with a short strength training protocol or no training. a similar aim is addressed after tens of elbow flexor muscles. subjects with relapsing remitting or progressive ms, will undergo transcutaneous electrical nerve stimulation (tens), strength exercises (sexerc), both tens and sexerc (comb) simultaneously, or sham stimulation without training (con) of both leg and arm muscles. force and fatigue measurements are performed before, directly after and three weeks after the training sessions and contain walking, fatigue, and strength assessments. main study parameters are changes in the scores of i) the six-minute walking test (6-mwt), ii) the perceived walking disability (msws-12) and iii) fatigue questionnaires (fss and mfis). additional study parameters are changes in muscle force and muscle fatigability.


Eligibility criteria:
inclusion criteria: * edss score \< 7 * msws score \> 30 * fss score \> 4 or mfis score \> 38. * no known cardiovascular disorder or having a positive advice on a sport medical examination exclusion criteria: * being a participant in an exercise study * having a psychiatric disorder * having cognitive or communication problems which reduces the capacity to understand instructions * planned a change in medication during the training period * having a neurological disorder other than ms * having cardiovascular disorders and no positive advice from a sport medical examination * having a pacemaker or another implantable electronic apparatus. * being pregnant
transfer of fresh versus frozen/thawed embryos in ivf cycles where gnrh agonist is utilized for oocyte maturation.

Conditions: Ovarian Hyperstimulation Syndrome; Infertility Drugs; Female

Summary: it has been suggested that in ivf cycles where gnrh agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. we hypothesize that the use of gnrh antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.


Eligibility criteria:
inclusion criteria: * woman at risk of ovarian hyperstimulation syndrome in ivf cycles for whom gnrh agonist was utilized for final oocyte maturation exclusion criteria: * patient's refusal to participate

Keywords: gnrh agonist ovarian hyperstimulation syndrome embryo cryopreservation
study of bevacizumab plus chemotherapy in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. before the treatment, the investigators detect the vegf-a,vegf-c,vegf-d,vegfr-1,vegfr-2,vegfr-3 expression in tumor tissue by ihc and detect those protein expression level in plasma by elisa. after at least 6 weeks treatment, the investigators detect again vegf-a,vegf-c,vegf-d expression level in plasma by elisa. the aim of the study is to identify whether those biomarkers could predict bevacizumab efficacy.


Eligibility criteria:
inclusion criteria: * more than 18-years old,male or female * pathologically approved as unresectable/metastatic colorectal cancer * kps \> 70% or ecog 0-2 * hgb \> 80 g/l, neut ≥ 1.5x109 /l, plt ≥ 80x109 /l; cr \< 1.5 x upper normality， * tb \< 1.5 x upper normality，ast or alt \< 2.5 x upper normality. * signed consent exclusion criteria: * other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer * pregnancy or in lactation * hgb \< 80 g/l, neut \< 1.5x109 /l, plt \< 80x109 /l; cr ≥ 1.5 x upper normality， tb ≥ 2.5 x upper normality，ast or alt ≥2.5 x upper normality，akp ≥ 2.5 x upper normality
macular retinoschisis and detachment associated with glaucomatous optic neuropathy

Conditions: Macular Retinoschisis; Macular Detachment; Normal Tension Glaucoma

Summary: clinical features, optical coherence tomography findings and surgical outcome in eyes with macular retinoschisis and detachment with normal tension glaucoma but without optic disc pit or high myopia were evaluated.


Eligibility criteria:
inclusion criteria: * the patients with macular retinoschisis and detachment associated with normal tension glaucoma exclusion criteria: * optic pit maculopathy, high myopia

Keywords: macular retinoschisis macular detachment vitrectomy
virtual mindfulness and weight management to mitigate risk of relapse and improve wellbeing in cancer survivors

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm; Obesity-Related Malignant Neoplasm

Summary: this clinical trial tests how well a virtual mindfulness and weight management program to mitigate risk of relapse and improve well being for obese cancer survivors in community practice and rural areas. obesity has been linked to increased risk for certain kinds of cancer and is the second highest modifiable risk factor for cancer. it is also well documented that having a cancer diagnosis and treatment is a stressful experience. it is hoped that an addition of a 10-minute mindfulness-based stress reduction exercise to the virtual positive health habits group focused on weight management can improve wellbeing and distress. virtual care options continue to extend the reach of medical providers to cancer survivors, particularly those in the rural setting. a virtual behavioral weight management program with an integrated mindfulness component may improve mood, coping strategies, stress management, and weight loss among community practice and rural obese cancer survivors.

primary objectives: i. to assess if a 12-week virtual weight management program with a mindfulness component will improve well-being of obese cancer patients with a specific focus on self-reported measures of depression and anxiety. ii. to assess if a mindfulness component added to the virtual behavioral weight management will promote weight loss, improve mood, and increase physical activity. outline: patients participate in a virtual behavioral weight management program with an integrated mindfulness component consisting of 12, 75-minute virtual group sessions over 12 weeks to help improve mood, coping strategies, stress management, and weight loss. patents also receive patient education handouts, view behavioral educational powerpoint presentations over 30 minutes, and wear a fitbit on study.

Eligibility criteria:
inclusion criteria: * 18 or over * identified stage i, ii, or iii cancer in remission * body mass index (bmi) of 30 or greater * english as a primary language * has access to a device with a camera (computer, tablet, or video capable phone) that has wifi and reliable internet access exclusion criteria: * unable to provide consent * eastern cooperative oncology group (ecog) performance status scale score of 3 or above
pulmonary function in patients recovering from covid19 infection : a pilot study

Conditions: COVID-19

Summary: the current state of knowledge shows the presence of respiratory sequelae after acute infection with covid-19 and the importance of these long-term respiratory dysfunctions have to be determined. aim of our study is describe diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from sars-cov-2 pneumonia at 3 and 6 months after the acute episode.

patients with confirmed covid-19 who had been discharged from chru hospital in limoges (france) will be included to follow the impact of severe acute respiratory syndrom coronavirus 2 on pulmonary function, diaphragm function and exercice capacity. surviving patients will be evaluated at 3 and 6 months after hospital discharge. the assesment will include diaphragm ultrasonography, spirometry (fev1,fvc), carbon monoxide transfert (tlco adjusted for haemoglobin), inspiratory an expiratory respiratory muscle strength (pimax and pemax) and 6 minutes walk distance (6mwd).the main outcome will be diaphragm excursion assessed by ultrasound.

Eligibility criteria:
inclusion criteria: * sars-cov-2 infection proven by rt-pcr. * patient hospitalised for the management of sars-cov-2 infection and included 3 months after the end of his hospitalisation at the chu of limoges. * patient of legal age. * patient affiliated to a social security regime. * patient having given informed consent exclusion criteria: * known pregnancy. * patients who are contraindicated to perform the 6-minute walk test. * patients unable to understand or adhere to the protocol. * patients deprived of liberty. * patients under court order, tutorship or curatorship. * minor patients

Keywords: lung function diaphragm ultrasonography chronic inflammatory rheumatism
a study to evaluate the safety and effectiveness of trastuzumab emtansine (t-dm1) as therapy in chinese participants with her2 positive advanced breast cancer

Conditions: Breast Cancer

Summary: this study is a post-marketing, observational, multicenter, prospective study. it will investigate the the safety and effectiveness of t-dm1 in the chinese population in real-world clinical practice.


Eligibility criteria:
inclusion criteria: * diagnosed with her2-positive, unresectable locally advanced or metastatic breast cancer before the start of t-dm1 treatment * had prior treatment for breast cancer which must contain a taxane and trastuzumab * get the treatment of t-dm1 for the first time after diagnosis of breast cancer exclusion criteria: * patients not receiving treatment for her2-positive breast cancer with t-dm1 according to standard of care and in line with the current summary of product characteristics (spc)/local labeling * has been previously treated with t-dm1 before current clinical visit * currently participating in any clinical trials * previously participated in any clinical trials investigating anti-her2 drug within 1 year of the initiation of t-dm1
a safety and efficacy study of sar405838 and pimasertib in cancer patients

Conditions: Neoplasm Malignant

Summary: primary objectives: to determine the recommended phase 2 dose of sar405838 / pimasertib combination therapy in patients with solid tumors. to assess the anti-tumor activities of sar405838 / pimasertib in patients with solid tumors. secondary objectives: to characterize the pharmacokinetic profile of sar405838 and pimasertib. to evaluate the pharmacodynamic effect of the sar405838 and pimasertib. to characterize genetic status in tumor tissue and circulating tumor dna.

the duration of the study for an individual patient will include a period to assess eligibility of up to 4 weeks, a treatment period of at least 6 weeks of study treatment, and an end-of-study visit at least 30 days (or until the patient receives another anti-cancer therapy, whichever is shorter) following the last administration of study drug.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of a solid tumor. * presence of locally advanced or metastatic disease with at least one measurable lesion. * ability to provide written informed consent. evidence of a personally signed informed consent. exclusion criteria: * age \<18 years. * eastern cooperative oncology group performance status of \>1. * inadequate functions of bone marrow, liver, and kidney. * positive pregnancy test in women of child-bearing potential. * pregnancy or breast-feeding. * extensive prior radiotherapy. * the patient has retinal degenerative disease, history of uveitis, or history of retinal vein occlusion, or history of retinal detachment, or has medically relevant abnormalities identified on screening ophthalmologic examination. * prior history of myositis or rhabdomyolysis. * recent major surgery or trauma, unhealing/open wounds. * the patient has had congestive heart failure, unstable angina, a myocardial infarction, cardiac conduction abnormality or pacemaker or a stroke within 3 months of entering the study. * the patient has a baseline corrected qt interval (qtc) \>480 ms or left ventricular ejection fraction (lvef) \<50% or less than the lower limit of normal. * the patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations. * unwillingness or inability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions. * unwillingness, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods. * recent history of acute pancreatitis. * clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that could affect the safety of the patient; alter the absorption of the study drugs; or impair the assessment of study results. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
the relationship between pain, balance and gait in people with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Balance Impairment; Gait Impairment; Pain

Summary: the balance, gait and pain in chronic obstructive pulmonary disease (copd) study will aim to investigate the link between balance and gait impairment, and high rates of pain in people with copd. this cross-sectional observational study will compare balance and gait outcomes for people with copd who have pain, to those who are pain free.


Eligibility criteria:
inclusion criteria: * have a spirometry confirmed diagnosis of copd as per global initiative for chronic obstructive lung disease (gold) guidelines * be 18 years or over at the point of recruitment * be able to communicate with good verbal english or use adaptive equipment to communicate. * be able to complete test procedures * stable copd (six weeks clear of exacerbation) * no uncorrected visual or somatosensory disturbance exclusion criteria: * no other conditions that may affect balance or gait e.g. neurological or vestibular conditions * recent exacerbation of copd (within the last six weeks) * unable to provide written informed consent * unable to speak english or no translation options available * any other acute health conditions that would make activity unsafe e.g. acute infection, unstable cardiac disease.

Keywords: copd, balance, gait, pain
effect of prenatal education on perceptions of epidural acceptance

Conditions: Labor Pain

Summary: the purpose of the study is to determine if targeted prenatal educational program on womens' perceptions of epidural increases the acceptance of intrapartum epidural analgesia relative to the control group.

racial/ethnic disparities exist in the proportion of patients receiving epidural analgesia. the purpose of our study is to determine if culturally-sensitive educational program targeting womens' perceptions of epidural increases the acceptance of intrapartum epidural use.

Eligibility criteria:
inclusion criteria: 1. women with viable intrauterine gestation seeking prenatal care 2. candidates for intrapartum epidural analgesia exclusion criteria: 1. intrapartum epidural analgesia is contraindicated 2. trial of labor is contraindicated. 3. patients planning an elective cesarean

Keywords: intrapartum pain management, epidural
surveillance of patients with precancerous lesions of the stomach

Conditions: Gastric Cancer; Gastric Intestinal Metaplasia; Gastric Atrophy; Gastric Dysplasia

Summary: the project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals. implementing risk stratification only high risk individuals will be offered and performed endoscopic surveillance.

gastric cancer is still an important healthcare problem with significant mortality rates. latvia is a high incidence country of gastric cancer. unfortunately most of the gastric cancer cases in latvia are diagnosed at late stages when the treatment is substantially less effective. ideally, gastric cancer could be prevented by detecting gastric precancerous conditions/lesions and identifying those individuals at high-risk of progressing to cancer to the follow-up. population based endoscopic screening for gastric cancer is not recommended for the early detection of gastric cancer generally deemed not to be cost-effective. however, in the absence of screening, patients present with advanced disease, and prognosis is poor. targeted endoscopic surveillance strategies for gastric cancer should be introduced following the principles of the recent european guidelines: management of precancerous conditions and lesions in the stomach (maps) (dinis-ribeiro, areia et al. 2012). the project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals. implementing risk stratification only high risk individuals will be offered endoscopic surveillance.

Eligibility criteria:
inclusion criteria: patients undergoing upper endoscopy motivation to participate in the study signed consent exclusion criteria: known gastric cancer unwillingness or inability to co-operate

Keywords: gastric precancerous lesions gastric cancer gastric intestinal metaplasia gastric atrophy gastric dysplasia
idylla egfr lung trial

Conditions: Lung Cancer; Technology; Oncology

Summary: this retrospective, observational study will compare the results of a biocartis' egfr mutation test on the idylla platform with test results from soc pathology results from tissue biopsies in the same setting. a comparable rapid testing platform for egfr may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies. up to 150 samples will be tested and compared with existing results.

this study will compare the results of a biocartis' egfr mutation test on theidylla platform with test results from standard of care (soc) pathology results from tissue biopsies. the idylla™ egfr mutation test, performed on the biocartis idylla™ system, is an in vitro diagnostic test for the qualitative detection of exon 18, exon 20, and exon 21 mutations. additionally, exon 19 deletions and exon 20 insertions in the egfr oncogene. a rapid testing platform for egfr may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies.

Eligibility criteria:
inclusion criteria: * patients diagnosed with primary lung cancer * data from primary diagnosis must be included in pathology report or data entry. * detailed pathology report included for all samples exclusion criteria: * limited or no tissue available * only tissue available is from fine needle aspiration * tissue blocks older than 5 years old

Keywords: protean biodiagnostics